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Abstract: Evidence-based medicine integrates the best
available data in decision making, with the goal of minimizing
physicians’ and patients’ subjectivity. In 2006, the American
Society of Clinical Oncology edited clinical practice guidelines
for the use of larynx preservation strategies. The objective of
this review was to evaluate the current levels of evidence for
glottic squamous cell carcinoma. Current guidelines for early
stage glottic cancer are based on low-level evidence. Conser-
vation surgery (open or transoral) and radiation therapy are all
valid options for T1 and selected T2 lesions. For advanced
lesions, surgery and combined chemotherapy and radiation
are options. High-level evidence favors combined chemother-
apy and radiation therapy or altered fractionation radiation
therapy as nonsurgical strategies for organ preservation, com-
pared with radiation therapy alone. The optimal combination of
chemotherapy, targeted therapy, and radiation therapy
remains to be demonstrated, however, and for high-volume
tumors, total laryngectomy may still be warranted. VC 2011
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Evidence-based medicine is the ‘‘conscientious,
explicit and judicious use of current best evidence in
making decisions about the care of individual
patients,’’ and ‘‘integrating experience with the best
available data in decision making.’’1 The role of clini-
cal research is to allow us to rationalize and refine
our practices for the benefit of our patients: ‘‘Experi-
ence is good but wisdom is better. On what should we
rely for treatment decisions—anecdotes, opinions, and
persuasion, or more objective data, systematic
reviews, and thoughtful interpretation of available
clinical reports? Use of the best information, thus
minimizing bias and opinion, is the key element that
separates ethical medical practitioners from quacks
and charlatans.’’2
But why do we need evidence-based medicine? As
technology advances, there is an increasing number of
therapeutic options at our disposal. As globalization
advances, we see the spectrum of the variations in clin-
ical practice expand. Modern medicine includes the
patient in therapeutic decision making, with informed
consent obtained based on objective information and
sound communication with healthcare providers.
Finally, as knowledge in decision psychology pro-
gresses, it has become increasingly apparent that
physicians are not as objective as they think they are
when making decisions for patient treatment.1
Evidence in medicine can be classified as ‘‘high-
level evidence,’’ evidence with high statistical power
and a low risk of bias, and ‘‘low-level evidence’’ with
low statistical power (or none at all) and a high risk
of bias. Between the highest and lowest levels, groups
of experts throughout the world have developed vari-
ous classification schemes, to compare different medi-
cal studies according to their methodology, statistical
power, and risk of bias, generally with 4 or 5 levels.
In 2006, the American Society of Clinical Oncology
edited clinical practice guidelines for the use of larynx-
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preservation strategies, based on a systematic review of
the literature.3 The objective of this review was to evalu-
ate the level of current evidence concerning these treat-
ment options for glottic squamous cell carcinoma. For
the purposes of this review, we have chosen a 5-level
classification to rate levels of evidence4: level I, large
randomized trials or meta-analyses of randomized trials;
level II, small randomized trials; level III, nonrandom-
ized studies with contemporaneous controls; level IV,
nonrandomized studies with historical controls; level V,
case studies with no controls.
QUESTIONS
1. What is the evidence in favor of any 1 particular
type of treatment for early-stage glottic tumors (T1a)5
without anterior commissure (AC) involvement?
High rates of local control and laryngeal function
preservation have been shown for patients with early
glottic tumors using radiation therapy (RT), transoral
laser resection, or open partial laryngeal surgery. The
reported rates of local control with conservation la-
ryngeal surgery for T1 glottic carcinoma—transoral
laser resection or traditional open partial laryngecto-
mies—range from 85% to 100%,6–46 and reported local
control with RT alone ranges from 84% to 95% (Table
1).47–66 These data are based on nonrandomized stud-
ies with historical or contemporaneous controls
(levels III and IV). A systematic review in the
Cochrane Database of Systematic Reviews found only
1 prospective randomized trial comparing RT and sur-
gery.67 That study was fraught with methodological
flaws, however, leading the authors of the review to
conclude that ‘‘there is currently insufficient evidence
to guide management decisions on the most effective
treatment.’’ To date, no well-conducted prospective
randomized study has been performed to provide level
I or level II evidence in favor of any 1 of these differ-
ent types of approaches. The best level evidence to
date, comparing surgery (open or laser) to RT for T1a
glottic carcinoma, shows no final local control
or survival difference among these different treat-
ments (Table 2),46,50,68 although 1 study46 (101
patients, level 3 evidence) found a significant
improvement in final laryngeal preservation for
patients initially treated surgically.
The current evidence regarding exclusive chemo-
therapy for treating glottic tumors is based on retro-
spective and prospective nonrandomized studies (level
IV) and shows a rate of local control with chemother-
apy alone to be in the range of 8% to 12% of all
patients initially treated with induction chemother-
apy for T1 to T3 glottic tumors.69 Thus, in a compari-
son of treatment modalities, the (low-level) evidence
suggests that surgery and RT provide higher initial
local control rates than those of exclusive
chemotherapy.
The majority of the evidence (level III) shows that
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results in terms of voice outcomes and voice-related
quality of life.70–75 However, 1 study found a better
voice handicap score after laser surgery versus RT,76
and 2 other studies found that voice after RT was bet-
ter than that after laser surgery77,78 (all level III
studies). Voice results depend on the depth of the
laser resection, but level IV evidence shows that voice
can return to normal for a number of patients (45% of
patients in the study by Vilaseca et al79). This evi-
dence reflects the fact that not all tumors classified as
T1a are the same. They differ in depth of invasion of
the thyroarytenoid muscle. Depth of invasion may
constitute a bias in retrospective studies and a major
bias when comparing retrospective studies from dif-
ferent centers. Level III evidence shows that the post-
operative morbidity is lower with transoral laser
resection than that with open conservation surgery,
and that, despite comparable oncologic outcomes,
transoral resection has for the most part replaced
open surgery for tumors classified as T1a not involv-
ing the AC.80
What criteria then can be used to choose from
among these 2 treatment options if there is no strong
evidence in favor of 1 treatment over the other in
terms of local control and voice-related quality
of life? Cost is increasingly being integrated into
medical decision making and expert-driven recom-
mendations. Four level III studies (prospective non-
randomized) have shown that RT for T1 glottic
carcinoma is significantly more costly than transoral
laser resection, even though the calculation of cost
varies among countries.70–72,81 Technical aspects of
both treatments are also a consideration. Transoral
laser resection may not be possible because of
patient morphology or comorbidities, or may not be
possible because of the absence of a laser or a sur-
geon experienced in the technique. Alternatively, the
availability and logistics of 6 to 7 weeks of RT and
the need for careful cancer follow-up also become de-
cision-making factors. Finally, after a full discussion
and complete patient information, physician and
patient preferences also may be taken into account.
2. What is the evidence for treatment of T1a or
T1b glottic tumors involving the AC?
Cancers involving the AC pose a particular ana-
tomical problem for tumor spread because of the prox-
imity of the thyroid cartilage to the mucosa, the
absence of perichondrium or conus elasticus, the ab-
sence of anatomic barriers to tumor spread toward
the petiole of the epiglottis or to the cricothyroid
membrane, and the early ossification of the cartilage
at this level, which lowers its resistance to invasion
by the tumor. Deep extension at this level may have
no effect on vocal fold mobility, leading to a risk of
understaging.82,83 The small size of the region and
the early ossification of the cartilage contribute to the
difficulties in radiological staging and diagnosis of
cartilage invasion. CT and MRI criteria to optimize
the diagnosis of thyroid cartilage invasion are still
being assessed, and under-staging or overstaging still
occur in 25% to 50% of cases.83–86 Finally, adequate
exposure of the AC for transoral laser resection is
challenging in some patients.87
As Bradley et al83 clearly show in their compre-
hensive review, AC involvement for T1 tumors can
mean many things. T1a tumors involving 1 cord up to
the ipsilateral half of the AC are different from super-
ficial T1b tumors involving both cords and the AC
and from T1b tumors arising at the AC itself, with or
without infiltration, ulceration, or spread to the vocal
folds. It is also clear from this review that there has
been no study directly comparing treatment modal-
ities, such as RT, open surgery, or transoral laser sur-
gery, for comparable tumors involving the AC, taking
into account the differences in subtypes of AC
involvement, which do not appear in the TNM classi-
fication. Scarring of the AC after either surgery or RT
generally results in poor voice quality.
Furthermore, the existing literature includes het-
erogeneous populations of tumors, mixing the results
of superficial and infiltrating tumors, and tumors
classified T1a, T1b, and T2.83
The bulk of the literature concerning AC lesions
aims at determining whether AC involvement is a
risk factor for reduced local control. Most of these
studies include T1a, T1b, and T2 tumors involving
the AC, so that individualizing information regarding
T1 tumors with AC involvement is difficult. These
Table 2. Highest-level evidence for treatment options for T1/T1a laryngeal carcinoma.
Reference
No. of
patients Methodology Group Outcome
Evidence
level
Gourin et al68 89 Retrospective nonrandomized
cohort, T1 all laryngeal sites
RT vs surgery Survival: no difference III
Jones et al50 364 Retrospective nonrandomized






Initial local control: no difference III
Stoeckli et al46 101 Retrospective nonrandomized
cohort, T1 glottic tumors
RT vs laser Initial local control, survival: no difference
Final laryngeal preservation: initial surgery
better than RT
III
Abbreviation: RT, radiation therapy.
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retrospective studies provide conflicting level III and
level IV evidence (Tables 1 and 3), but it would seem
that at least certain subtypes of tumors involving the
AC (infiltrating tumors arising at the AC itself) are of
worse prognosis than tumors that do not involve the
AC.83 The literature, however, does not provide high-
level evidence as to the optimum treatment for these
lesions. Rates of local control and laryngeal preserva-
tion ranging from 75% to 98% have been reported
from retrospective studies of T1 tumors involving the
AC using RT,47,48,83 open surgery,12,88 and transoral
laser resection.34–39
A recent retrospective study by Sachse et al89
(level III, Table 3) found no difference between open
surgery and transoral laser resection for T1 or T2
tumors involving the AC, but showed that local con-
trol was significantly decreased if the AC was
involved, compared with tumors not involving the
AC. Bron et al7 and Zohar et al90 both found that
surgery provided better initial local control than RT.
Rucci et al91 retrospectively compared their surgical
and radiotherapy cohorts of tumors with AC involve-
ment and found that surgery as first-line treatment
provided significantly better local control (86% vs
74%), but that for ‘‘pure AC cancers’’ RT provided
better initial local control, although salvage surgery
was less effective after RT. This study illustrates the
heterogeneity of the subgroups of tumors involving
the AC, the bias inherent in retrospective studies,
and the limitations of comparing these studies.
In light of the above-cited evidence (levels III–IV)
there is no evidence favoring surgery over RT for T1
tumors involving the AC. For laryngeal tumors in
general, Silver et al79 recently analyzed the decline in
open surgery. As a result of the morbidity of open sur-
gery compared with that of transoral laser resection
or RT, these latter techniques have largely sup-
planted open conservation surgery for early stage la-
ryngeal cancers. For early-stage tumors, open surgery
is currently mostly reserved for recurrences.80,92 In
some cases, however, open surgery should still be con-
sidered an option as first-line treatment, in accord
with the experience and technical possibilities of the
surgeon and the radiation oncologist.93 Other factors
that can influence this decision include the ease of op-
erative exposure and sufficient possibilities for close
patient follow-up.
3. What treatment should be favored for higher
classification glottic tumors (T2) with or without
impaired vocal fold mobility?
Comparing retrospective case series with histori-
cal controls (level IV evidence), the initial local control
for T2 tumors with normal vocal fold mobility treated
with RT is comparable to the results of open surgery
and transoral laser resection, ranging from 84% to
95% (Table 1).8,9,19,40,41,47,48 Level III studies do not
provide compelling evidence in favor of surgery ver-
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supracricoid partial laryngectomy as opposed to a ver-
tical laryngectomy to optimize local control if open
surgery is chosen, however.19
For the subgroup of T2 tumors with impaired
vocal fold mobility, local control with RT alone falls to
76% (at best).47,48,94–96 Similarly, Peretti et al40,41
found a significant decrease in local control with
transoral laser resection for T2 tumors with deep
extension involving the paraglottic space or extending
to the roof of the ventricle and the false vocal fold
(17%), compared with the entire group of tumors clas-
sified as T2 (77%). This evidence (level III) empha-
sizes, yet again, the bias inherent in comparing T2
tumors since not all T2 tumors are similar, and they
do not have the same prognosis.
Retrospective studies (level IV) of supracricoid
partial laryngectomy for patients with T2 tumors
with impaired vocal fold mobility show a high rate of
local control (88% to 94%), albeit at the cost of remov-
ing three fourths of the larynx and a large portion of
the structures not involved by the tumor.33,97,98 Thus,
for T2 tumors with impaired mobility, level IV evi-
dence seems to favor open conservation surgery over
RT or transoral laser resection when local control is
the endpoint. However, voice function, the risk of per-
sistent aspiration, and the higher risk in elderly
patients are other factors to integrate into decision
making.
There is no evidence directly comparing
conservation surgery (open or transoral) with chemo-
radiation or other nonsurgical organ preservation pro-
tocols (RT with cetuximab or altered fractionation
schedules) for T2 tumors. Outcomes of prospective
randomized studies (level I evidence) for stage III and
stage IV tumors (including those classified as T2Nþ)
show better results for primary chemoradiation with
cisplatin versus RT alone or versus induction chemo-
therapy followed by RT,99 but also for RT plus cetuxi-
mab versus RT alone,100 and for altered-fractionation
schedules versus RT alone.101 When conservation sur-
gery is not possible for a T2 tumor, attributed to tu-
mor extensions or lack of local surgical possibilities,
high-level evidence would favor chemoradiation, RT
plus cetuximab, or altered-fractionation RT over RT
alone for organ preservation.
For T2 tumors with impaired vocal cord mobility
amenable to conservation surgery, there is only low-
level evidence to guide treatment decisions. As stated
in the American Society of Clinical Oncology’s guide-
lines, tumor evaluation, patient selection, and ‘‘local
expertise’’ are necessary but provide only subjective
elements for decision making. The relative morbidity
of each approach must be weighed, but has never
been directly compared. Open conservation surgery
exposes patients to permanent dysphonia and often
some degree of dysphagia or aspiration, and requires
an experienced surgical team. Nonsurgical organ
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carry hematologic, renal, and/or cutaneous toxicities,
and RT exposes patients to late complications such as
laryngeal edema and fibrosis, which can lead to dys-
phagia, dysphonia, and/or dyspnea.102,103
4. Is there evidence favoring a particular organ
preservation strategy for higher-classification (T3–T4)
tumors arising at the glottic level?
There are no studies directly comparing organ-
preservation surgery with nonsurgical organ-preser-
vation protocols for advanced-stage laryngeal tumors
in a prospective manner with comparable patient
groups. Given the evidence (level IV) showing excel-
lent local control, functional organ preservation, and
survival for T3 laryngeal carcinoma using supracri-
coid partial laryngectomy,27,104 this approach remains
an option for eligible patients, providing that the sur-
gical expertise is available. Supracricoid partial laryn-
gectomy remains an alternative to total laryngectomy
(TL) or nonsurgical organ preservation for selected
patients with tumors classified as T3 and T4a.
Survival and local control by TL followed by RT
have not been bettered by the use of nonsurgical
organ-preservation strategies. In the only prospective
randomized study comparing TL and RT with nonsur-
gical organ preservation, the Department of Veterans
Affairs (VA) Laryngeal Cancer Study,105 disease-spe-
cific survival was shown to be the same in the 2
groups (2-year overall survival 68% in both groups,
level I evidence). A further prospective randomized
trial, the Radiation Therapy Oncology Group (RTOG)
91-11 Study,99 comparing 3 arms—concurrent chemo-
radiation (CRT), induction chemotherapy, and RT
(the VA protocol) and RT alone—showed that overall
survival did not differ among the 3 groups (2-year
survival of 74%, 76%, and 75%, respectively). Disease-
free survival was significantly better in the 2 arms
with chemotherapy, however (61% and 52% vs 44%
for RT alone). Organ preservation was better for the
CRT arm (88% vs 75% vs 70% at 2 years). Local con-
trol and survival have also been shown to be higher
with accelerated and hyperfractionated radiotherapy
compared with conventional RT (level I evidence).101
RT combined with cetuximab has been shown to
improve survival for patients with advanced head and
neck tumors (level I), although this improvement was
not significant for the subset of patients with
advanced laryngeal cancer.100 Finally, the addition of
docetaxel to induction chemotherapy improves onco-
logical results and organ preservation in advanced-
stage tumors compared with cisplatin and fluorouracil
alone followed by chemoradiation (level I).106,107 A
meta-analysis of large randomized trials (level I evi-
dence)108,109 has shown improved survival for CRT
using cisplatin, compared with sequential treatments
or RT alone, but the role of newer therapies (taxanes
and targeted therapies) remains to be examined.
Lower-level evidence, however, challenges the
notion that nonsurgical organ preservation strategies
provide survival rates comparable to the ‘‘gold stand-
ard’’ of total laryngectomy followed by RT (Table
5).68,99–101,105–107,109–111 An analysis of the National
Cancer Data Base (NCDB) information on laryngeal
cancer led Hoffman et al110 to demonstrate that, con-
trary to most other cancers, 5-year overall survival
for laryngeal cancer had decreased significantly from
the period of 1985 to 2001, from 68.1% to 64.7%. This
decrease paralleled a decline in patients’ socioeco-
nomic status over that period. A subgroup analysis,
however, showed that this decrease was significant
for T3N0 supraglottic cancer, but not for T4N0 or
T3Nþ supraglottic tumors, and that the decrease for
glottic tumors overall was significant only when com-
paring 1985–1987 with 1994–1996. Survival after che-
moradiation was not significantly different from
survival after surgery with RT for T3N0 laryngeal or
T3N0 glottic tumors, but was worse after RT
alone.110,112,113 A smaller database study came to sim-
ilar conclusions for stage III laryngeal tumors, show-
ing no difference in survival between CRT and TL.111
This study, however, showed significantly better sur-
vival after TL compared with CRT or RT for stage IV
tumors.111 This study also showed a significant associ-
ation between survival and race, socioeconomic sta-
tus, and access to healthcare. Finally, a recent large
retrospective case series demonstrated improved sur-
vival for T4 tumors treated surgically compared with
CRT or RT.68
Furthermore, despite the impeccable methodology
and high statistical power of these randomized con-
trolled trials, there still remains a certain risk in
applying the results of these studies to all patients
with stage III and stage IV tumors.114 A close look at
the patients included in the RTOG 91-11 study, for
example, reveals that approximately two thirds of the
tumors were supraglottic tumors, 40% of the patients
had mobile vocal folds, only 10% of the tumors were
classified as T4, and the performance status was
>80% for approximately 95% of the patients.99 This
study specifically excluded ‘‘large volume’’ T4 disease,
defined as ‘‘tumor penetrating through the cartilage
or extending more than 1 cm into the base of the
tongue.’’99,112 The clinical guidelines, or ‘‘standard of
care’’ determined by the American Society of Clinical
Onology in 20063 state that ‘‘evidence supports the
use of larynx-preservation approaches for appropri-
ately selected patients without a compromise in sur-
vival; however no larynx-preservation approach offers
a survival advantage compared with TL.’’ The optimi-
zation of nonsurgical organ preservation (as with sur-
gical organ preservation strategies) still relies on
adequate patient selection. For appropriately selected
patients, the options of CRT, induction chemotherapy
with taxanes, RT and cetuximab, and altered fractio-
nation RT all provide a high level of organ preserva-
tion without compromising survival, compared with
RT.
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There is currently no evidence directly comparing
these different nonsurgical organ-preservation proto-
cols (chemoradiation, RT plus cetuximab, hyper-
fractionated or accelerated RT, or induction
chemotherapy with taxanes) among each other, and
only the VA study directly compared their protocol
with TL plus RT, still considered as the ‘‘gold stand-
ard’’ in terms of local control and survival for locally
advanced laryngeal carcinoma. Thus, for nonsurgical
organ preservation, in light of these more recent
treatment options, the optimal strategy is still
unclear, and for ‘‘large volume’’ laryngeal carcinoma
with widespread cartilage or tongue base infiltration,
the current trend still tends to favor TL followed by
RT.112,113,115,116
DISCUSSION
The aim of this review was to show that the levels of
evidence for treatment selection remain very low. The
American Society of Clinical Oncology published clini-
cal practice guidelines in 2006, with recommendations
based on current evidence. These guidelines admit
that the recommendations for T1T2 lesions of the glot-
tis are based on ‘‘comparison of outcomes from case
series/prospective single-arm studies’’ (level III). The
recommendations reflect this lack of high-level evi-
dence. RT, open surgery, or transoral laser resection
are all options for patients with tumors classified as
T1T2 in these guidelines. The authors do make clear
that multimodality therapy is not recommended for
patients with these early-stage lesions, not because
evidence shows a lack of advantage, but rather, it
seems, from a risk–benefit analysis, where the morbid-
ity of multimodality treatment probably outweighs the
oncological benefit for these patients whose prognosis
remains excellent with single-modality therapy.
Although treatment selection may be single modality,
all patients benefit from an expert multidisciplinary
evaluation in which all treatment options and func-
tional issues are evaluated and discussed.
A major advantage of the guidelines is
to emphasize organ-preservation strategies, whether
surgical or nonsurgical, and to emphasize the need
for a multidisciplinary teamwork approach for each
patient. The tracheostoma and loss of a physiological
voice after TL decrease quality of life.117–119 If similar
oncological outcomes, without other functional mor-
bidity, can be obtained with alternatives to TL, they
are to be preferred, whether with organ-preservation
surgery or nonsurgical organ-preservation strategies.
Future prospective randomized studies with
adequate statistical power should aim to answer the
questions not addressed in the current literature. It
has become apparent that all T1a tumors are not
equal, in terms of depth of vocalis muscle invasion.
One question is: for T1a tumors with comparable
depth of vocal fold invasion, which treatment provides
the best voice quality and voice-related quality of life?
It has become evident that not all tumors involving
the AC are of worse prognosis, but that some sub-
types are and may require more aggressive treat-
ment. For each subgroup of T1 tumors involving the
AC (T1a, T1b superficial and bicordal, or infiltrating
T1b arising at the AC), which treatment provides the
best local control? Which treatment provides the best
ultimate laryngeal preservation? Which treatment
provides the best voice outcome? From studies com-
paring different subtypes of tumors classified as T2, it
is apparent that not all T2 tumors are the same. For
superficial tumors classified as T2, how do different
treatment modalities compare? For T2 tumors with
impaired mobility amenable to conservation surgery,
how does organ-preservation surgery compare with
nonsurgical strategies in terms of local control, final
organ-preservation, and quality of life? Finally,
among the nonsurgical organ-preservation strategies
for advanced laryngeal cancer now at our disposal,
how do they compare in terms of local control, final
organ preservation, and acute and late toxicities and
when is a TL still preferable?
Prospective randomized trials with comparable
cohorts are necessary to improve our levels of evidence
for treatment decision making. Trials are currently
under way concerning nonsurgical organ-preservation
strategies for patients with advanced laryngeal cancer.
These prospective multicenter trials providing a high
level of evidence often involve support from the private
sector, but even these trials may be fraught with bias in
patient selection and evaluation of endpoints,116 arising
from the subjective nature of clinical tumor staging/clas-
sification (evaluation of tumor extensions and vocal fold
mobility). Information from radiological studies is not
always pertinent in the initial evaluation or evaluation
of response to treatment for laryngeal cancer because of
the complexities and subjectivity of the interpretation of
laryngeal imaging. Finally, results of complex clinical
trials may not be reproducible in the general setting, as
a result of epidemiological factors, and patient self-selec-
tion for clinical trials that may constitute a bias toward
better outcomes, in and of itself.120 Because of the heter-
ogeneity observed when comparing past clinical trials,
new recommendations115 attempt to redefine inclusion
criteria, pertinent stratification variables, and accepta-
ble endpoints for future larynx-preservation clinical tri-
als. Developing clinical trials involving surgery meets
with similar difficulties in selecting patients, in eliminat-
ing bias in patient selection and surgical expertise in dif-
ferent centers, and in financing studies involving
surgery. Academic support for this type of prospective
study is necessary. Finally, outcomes in laryngeal cancer
are in part related to socioeconomic inequalities, or the
‘‘deprivation gap’’ described by Rachet et al121 that
healthcare systems and governments are currently striv-
ing to remedy.
The future holds even more questions. Molecular
profiling for treatment selection is still in its infancy
for laryngeal cancer, but research in this domain will
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give way to new therapeutic paradigms. Robotic sur-
gery, future miniaturization of robotic instruments,
image-guided surgery, and other technological advan-
ces may improve tumor visualization and resection,
and enlarge the indications for transoral minimally
invasive surgery. Finally, and in the very near future,
better patient selection based on tumor biology, new
targeted treatments, and new combined modality
therapies will be offering even more options for organ
preservation.
CONCLUSIONS
Current treatment guidelines for early-stage glottic
cancer are based on low-level evidence. Conservation
surgery (open or transoral laser resection) and RT are
all still valid options for treating T1 and selected T2
glottic lesions. Subjective selection criteria are still
the basis for treatment choice for these early-stage
lesions. For advanced lesions not amenable to conser-
vation surgery, high-level evidence favors combined-
modality therapy, chemotherapy and RT, or altered
fractionation RT, as nonsurgical strategies for organ
preservation, compared with RT alone. The optimal
combination of chemotherapy, targeted therapy, and
RT remains to be demonstrated. Finally, for large vol-
ume, infiltrating lesions, TL followed by RT still has
its place in our armamentarium.
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